RU2015101081A - Стабилизированный gp120 - Google Patents

Стабилизированный gp120 Download PDF

Info

Publication number
RU2015101081A
RU2015101081A RU2015101081A RU2015101081A RU2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A
Authority
RU
Russia
Prior art keywords
polypeptide
seq
stabilized
fusion protein
hiv
Prior art date
Application number
RU2015101081A
Other languages
English (en)
Russian (ru)
Inventor
Андреа КАРФИ
Анту ДЕЙ
Аэмро КАССА
Индреш СРИВАСТАВА
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2015101081A publication Critical patent/RU2015101081A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015101081A 2012-06-18 2013-06-17 Стабилизированный gp120 RU2015101081A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
US61/661,050 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (1)

Publication Number Publication Date
RU2015101081A true RU2015101081A (ru) 2016-08-10

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015101081A RU2015101081A (ru) 2012-06-18 2013-06-17 Стабилизированный gp120

Country Status (14)

Country Link
US (1) US20150183835A1 (cg-RX-API-DMAC7.html)
EP (1) EP2861249A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015521592A (cg-RX-API-DMAC7.html)
KR (1) KR20150023735A (cg-RX-API-DMAC7.html)
CN (1) CN104619338A (cg-RX-API-DMAC7.html)
AU (1) AU2013279456A1 (cg-RX-API-DMAC7.html)
CA (1) CA2876762A1 (cg-RX-API-DMAC7.html)
IL (1) IL235898A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014KN02740A (cg-RX-API-DMAC7.html)
MX (1) MX2014014682A (cg-RX-API-DMAC7.html)
RU (1) RU2015101081A (cg-RX-API-DMAC7.html)
SG (1) SG11201407995RA (cg-RX-API-DMAC7.html)
WO (1) WO2013189901A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408840B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
US10010605B2 (en) * 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3426291A1 (en) 2016-03-09 2019-01-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
EP3697440A1 (en) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (fr) * 1998-11-27 2003-04-25 Orstom Mutants de la gp120 et leurs applications biologiques
WO2001000648A1 (en) * 1999-06-25 2001-01-04 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー V3ループに改変を有するhivenvタンパク質
US9175070B2 (en) * 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use

Also Published As

Publication number Publication date
KR20150023735A (ko) 2015-03-05
AU2013279456A1 (en) 2014-12-18
SG11201407995RA (en) 2015-01-29
WO2013189901A1 (en) 2013-12-27
IL235898A0 (en) 2015-01-29
ZA201408840B (en) 2016-08-31
JP2015521592A (ja) 2015-07-30
IN2014KN02740A (cg-RX-API-DMAC7.html) 2015-05-08
CA2876762A1 (en) 2013-12-27
MX2014014682A (es) 2015-03-04
US20150183835A1 (en) 2015-07-02
CN104619338A (zh) 2015-05-13
EP2861249A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
JP2015521592A5 (cg-RX-API-DMAC7.html)
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ622048A (en) Hybrid polypeptides including meningococcal fhbp sequences
US8790898B2 (en) Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
JP2013507907A5 (cg-RX-API-DMAC7.html)
JP2015214545A5 (cg-RX-API-DMAC7.html)
JP2015529678A5 (cg-RX-API-DMAC7.html)
HRP20160798T1 (hr) Rekombinantni antigeni iz rsv
RU2014134365A (ru) Вакцины против clostridium difficile, включающие рекомбинантные токсины
SI2340038T1 (en) A biochemically stabilized HIV-1 ENV TRIMER vaccine
RU2014135053A (ru) Иммуногены для вакцинации против вич
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
JP2009520758A5 (cg-RX-API-DMAC7.html)
RU2015119523A (ru) Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
JP2010539901A5 (cg-RX-API-DMAC7.html)
JP2012102105A5 (cg-RX-API-DMAC7.html)
IN2014KN02740A (cg-RX-API-DMAC7.html)
JP2016520534A5 (cg-RX-API-DMAC7.html)
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа
PH12013501728A1 (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
RU2020106669A (ru) Синтетические белки и пути их терапевтического применения

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170726